Optimal Duration of Anticoagulation Following Venous Thromboembolism Among Patients With and Without Inherited Thrombophilia

2001 ◽  
pp. 288-309
Keyword(s):  
Venous Thromboembolism ◽  
Inherited Thrombophilia ◽  
Optimal Duration

Venous Thromboembolism: Genetics and Thrombophilias

2021 ◽  
Vol 42 (02) ◽  
pp. 271-283
Author(s):  
Manila Gaddh ◽  
Rachel P. Rosovsky
Keyword(s):  
Clinical Practice ◽  
Venous Thromboembolism ◽  
Family History ◽  
Morbidity And Mortality ◽  
Inherited Thrombophilia ◽  
Risks And Benefits ◽  
Hereditary Thrombophilia ◽  
The World ◽  
The Future ◽  
History Of

AbstractVenous thromboembolism (VTE) is a major cause of morbidity and mortality throughout the world. Up to one half of patients who present with VTE will have an underlying thrombophilic defect. This knowledge has led to a widespread practice of testing for such defects in patients who develop VTE. However, identifying a hereditary thrombophilia by itself does not necessarily change outcomes or dictate therapy. Furthermore, family history of VTE by itself can increase an asymptomatic person's VTE risk several-fold, independent of detecting a known inherited thrombophilia. In this article, we will describe the current validated hereditary thrombophilias including their history, prevalence, and association with VTE. With a focus on evaluating both risks and benefits of testing, we will also explore the controversies of why, who, and when to test as well as discuss contemporary societal guidelines. Lastly, we will share how these tests have been integrated into clinical practice and how to best utilize them in the future.

scholarly journals Optimal Duration of Anticoagulation After Venous Thromboembolism

Circulation ◽  
2011 ◽  
Vol 123 (6) ◽  
pp. 664-667 ◽  
Author(s):  
Samuel Z. Goldhaber ◽  
Gregory Piazza
Keyword(s):  
Venous Thromboembolism ◽  
Optimal Duration

scholarly journals Impact of Inherited Thrombophilia on Venous Thromboembolism in Children

Circulation ◽  
2008 ◽  
Vol 118 (13) ◽  
pp. 1373-1382 ◽  
Author(s):  
Guy Young ◽  
Manuela Albisetti ◽  
Mariana Bonduel ◽  
Leonardo Brandao ◽  
Anthony Chan ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Inherited Thrombophilia

Inherited thrombophilia and gestational venous thromboembolism

2003 ◽  
Vol 16 (2) ◽  
pp. 243-259 ◽  
Author(s):  
Rainer B Zotz ◽  
Andrea Gerhardt ◽  
Rüdiger E Scharf
Keyword(s):  
Venous Thromboembolism ◽  
Inherited Thrombophilia

scholarly journals Venous Thromboembolism and Its Risk Factors in Children with Acute Lymphoblastic Leukemia in Israel: A Population-Based Study

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2759
Author(s):  
Shlomit Barzilai-Birenboim ◽  
Ronit Nirel ◽  
Nira Arad-Cohen ◽  
Galia Avrahami ◽  
Miri Ben Harush ◽  
...  
Keyword(s):  
Risk Factors ◽  
Venous Thromboembolism ◽  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Univariate Analysis ◽  
Population Based ◽  
Population Based Study ◽  
Inherited Thrombophilia ◽  
Severe Hypertriglyceridemia

Venous thromboembolism (VTE) is a serious complication of acute lymphoblastic leukemia (ALL) therapy. The aim of this population-based study was to evaluate the rate, risk factors, and long-term sequelae of VTE in children treated for ALL. The cohort included 1191 children aged 1–19 years diagnosed with ALL between 2003–2018, prospectively enrolled in two consecutive protocols: ALL-IC BFM 2002 and AIEOP-BFM ALL 2009. VTEs occurred in 89 patients (7.5%). Long-term sequelae were uncommon. By univariate analysis, we identified four significant risk factors for VTEs: Severe hypertriglyceridemia (p = 0.005), inherited thrombophilia (p < 0.001), age >10 years (p = 0.015), and high-risk ALL group (p = 0.039). In addition, the incidence of VTE was significantly higher in patients enrolled in AIEOP-BFM ALL 2009 than in those enrolled in ALL-IC BFM 2002 (p = 0.001). Severe VTE occurred in 24 children (2%), all of whom had at least one risk factor. Elevated triglyceride levels at diagnosis did not predict hypertriglyceridemia during therapy. In a multivariate analysis of 388 children, severe hypertriglyceridemia and inherited thrombophilia were independent risk factors for VTE. Routine evaluation for these risk factors in children treated for ALL may help identify candidates for intervention.

Inherited Thrombophilia: Implications for Prevention and Treatment of Venous Thromboembolism

2009 ◽  
Vol 35 (07) ◽  
pp. 683-694 ◽  
Author(s):  
Antonio Coppola ◽  
Antonella Tufano ◽  
Anna Cerbone ◽  
Giovanni Di Minno
Keyword(s):  
Venous Thromboembolism ◽  
Inherited Thrombophilia ◽  
Prevention And Treatment

Extended Therapy for Primary and Secondary Prevention of Venous Thromboembolism

2010 ◽  
Vol 23 (4) ◽  
pp. 313-323 ◽  
Author(s):  
Susan E. Conway ◽  
Todd R. Marcy
Keyword(s):  
Health Care ◽  
Venous Thromboembolism ◽  
Secondary Prevention ◽  
Practice Guidelines ◽  
Anticoagulation Therapy ◽  
Patient Specific ◽  
First Episode ◽  
Care Providers ◽  
Primary And Secondary Prevention ◽  
Optimal Duration

Clinical practice guidelines currently suggest extended anticoagulation therapy for primary and secondary prevention of venous thromboembolism (VTE). The optimal duration of anticoagulation has been an active area of clinical investigation for patients undergoing orthopedic surgeries and those diagnosed with a first episode of unprovoked VTE. Practice guidelines, VTE incidence, clinical predictors/mediators, and clinical trial evidence is reviewed to help pharmacists and other health care providers make an informed, patient-specific decision on the optimal duration of anticoagulation therapy. Extended anticoagulation up to 5 weeks following orthopedic surgery for primary VTE prevention and indefinitely following a first episode of unprovoked VTE for secondary VTE prevention should be considered only if the risk of bleeding is not high and the cost and burden of anticoagulation is acceptable to the patient. The optimal duration of anticoagulation therapy for primary or secondary prevention of VTE should include the health care provider and patient making a decision based on evaluation of individual benefits, risks, and preferences.

Inherited Thrombophilia and Gestational Venous Thromboembolism

2003 ◽  
Vol 29 (2) ◽  
pp. 131-142 ◽  
Author(s):  
Jacqueline Conard ◽  
Marie-Hélène Horellou ◽  
Meyer-Michel Samama
Keyword(s):  
Venous Thromboembolism ◽  
Inherited Thrombophilia
Sign in / Sign up

Export Citation Format

Share Document